Advertisement

Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Most Read

  1. FDA greenlight for esketamine sheds light on ketamine’s potential

Company A-Z

Latest Content

Janssen’s esketamine nasal spray not recommended by NICE for NHS use

The UK’s pricing regulator the National Institute for Health and Clinical Excellence (NICE) has decided to not recommend Janssen’s Spravato (esketamine) nasal spray in combination with an oral antidepressant for adults with treatment-resistant major depressive disorder for routine National Health Service (NHS) use.

FDA greenlight for esketamine sheds light on ketamine’s potential

In March, the FDA approved Janssen Pharmaceuticals’ depression drug esketamine, a form of ketamine for use as a treatment for depression. Billed as the most exciting antidepressant in decades, the drug has an entirely new mechanism of action. So what does esketamine offer, and why is the FDA so sure the benefits outweigh the risks?

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Close
Close
Close

Go Top